Search

Search Constraints

You searched for: Author/Creator Gamis, Alan S.

Search Results

1. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Issue 7 (2nd July 2016)

2. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Issue 10 (29th June 2014)

3. AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Issue 16 (25th April 2014)

4. AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Issue 16 (25th April 2014)

5. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3‐ITD status: a report from the Children's Oncology Group. (25th March 2014)

6. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3‐ITD status: a report from the Children's Oncology Group. (25th March 2014)

7. Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. Issue 9 (4th July 2016)

8. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Issue 4 (11th October 2013)

9. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA. Issue 2 (17th November 2021)

10. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Issue 9 (2nd September 2018)